Oncimmune Holdings PLC PDMR Dealing (0850J)
December 18 2020 - 1:00AM
UK Regulatory
TIDMONC
RNS Number : 0850J
Oncimmune Holdings PLC
18 December 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, has been notified that Adam Hill, PDMR and
Chief Executive Officer, has purchased 5,764 ordinary shares of
GBP0.01 each in the Company ("Ordinary Shares") for GBP1.7348 per
share on 17 December 2020.
Following this transaction, Adam has a total interest in the
Company of 3,537,539 Ordinary Shares, representing approximately
5.6 per cent of the Company's issued Ordinary Share capital.
This announcement, including the notification below, is made in
accordance with the requirements of Article 19 of the EU Market
Abuse Regulation.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Adam Mark Hill
------------------------------------ --------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Oncimmune Holdings plc
------------------------------------ --------------------------------------
b) LEI 213800HCYIWT6YPI1I02
------------------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description Ordinary Shares of GBP0.01 each
of the financial
instrument,
type of instrument
Identification ISIN: GB00BYQ94H38
code
b) Nature of Purchase of shares
the transaction
------------------------------------ --------------------------------------
c) Price(s)
and volume(s)
-------------------- -------------
Price Volume
-------------------- -------------
GBP1.7348 5,764
-------------------------------------------------------------- -------------
d) Aggregated
information
- Aggregated Same as above
volume
- Price
e) Date of the 17 December 2020
transaction
------------------------------------ --------------------------------------
f) Place of London stock exchange, AIM
the transaction
------------------------------------ --------------------------------------
For further information:
Oncimmune Holdings plc
Ron Kirschner, General Counsel and Company Secretary
contact@oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKKOBNFBDDPBD
(END) Dow Jones Newswires
December 18, 2020 02:00 ET (07:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024